Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: CDER 2016 Novel Approvals Hold At 22 As US FDA Declines Cempra's Solithera

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.

Advertisement

Related Content

Primatene Mist CRL Underscores Challenges For OTC Asthma Treatments
Cempra's Solithera Draws FDA Complete Response Letter On Liver Risks
Do FDA Submission, Approval Declines Outside Cancer Signal Future Treatment Gaps?
Jardiance's Cardiovascular Benefit Claim Bodes Well For Other Products Too
Primatene OTC Asthma Inhaler Amended NDA Expected Second Quarter
CBER Approvals Hit A High Note For Director Midthun's Swan Song
Big Pharma's Winning Formula: Many Approvals, Narrow Markets

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119754

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel